Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Baxter
Medtronic
Harvard Business School
Merck

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CRIXIVAN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Crixivan, and what generic alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug.

This drug has forty-two patent family members in thirty-five countries.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indinavir sulfate profile page.

Drug patent expirations by year for CRIXIVAN
Drug Prices for CRIXIVAN

See drug prices for CRIXIVAN

Generic Entry Opportunity Date for CRIXIVAN
Generic Entry Date for CRIXIVAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CRIXIVAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oncology Institute of Southern SwitzerlandPhase 2
Emory UniversityPhase 4
National Institutes of Health Clinical Center (CC)Phase 1

See all CRIXIVAN clinical trials

Recent Litigation for CRIXIVAN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Gilead Sciences, Inc. v. Merck & Co., Inc.2016-07-06
Monsanto Company v. Syngenta Seeds Inc.2004-05-12

See all CRIXIVAN litigation

Pharmacology for CRIXIVAN
Synonyms for CRIXIVAN
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxyindan-1-yl]amino]-5-oxo-pentyl]-N-tert-butyl-4-(3-pyridylmethyl)piperazine-2-carboxamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide (non-preferred name)
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-5-oxopentyl)-N-(tert-butyl)-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-ylamino)-5-oxopentyl)-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
2-benzyl-5-[(2S)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-D-erythro-pentonamide
216884-06-9
2avo
2avs
2avv
2bpx
378I179
90708-EP2272516A2
90708-EP2298783A1
90708-EP2305640A2
90708-EP2305680A2
9MG78X43ZT
AB00698241-07
AC-20034
AC1L1U7I
AKOS000280989
AM84463
BDBM50067593
BIDD:GT0378
BIDD:PXR0141
C-23355
C07051
C36H47N5O4
CC-29506
CHEBI:44032
CHEMBL115
Compound J
Crixivan (TM)
CS-2930
CTK8E9721
D-erythro-Pentonamide, 2,3,5-trideoxy-N-((1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-((2S)-2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-
D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1S,2R),5(S))-
D-erythro-Pentonamide,2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-
DB00224
DTXSID4043802
HY-B0689
IDV
indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN:INN:BAN]
Indinavir [USAN]
Indinavir & IFNL1
Indinavir & IFNL2
Indinavir & IFNL3
Indinavir & IL-28A
Indinavir & IL-28B
Indinavir & IL-29
Indinavir & Interferon lambda-1
Indinavir & Interferon lambda-2
Indinavir & Interferon lambda-3
Indinavir & Interleukin 28A
Indinavir & Interleukin 28B
Indinavir & Interleukin 29
Indinavir anhydrous
Indinavir, Sulfate (1:1)
J-008694
KB-296154
KS-5060
L-735 524
L-735,524
L-735524
L735,524
LS-173382
MK-639
MK1
MK639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-01
NCGC00159460-03
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
RT-013332
SC-26523
SCHEMBL6317
UNII-9MG78X43ZT
ZINC22448696

US Patents and Regulatory Information for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 RX Yes Yes   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 RX Yes No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998   Start Trial   Start Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000   Start Trial   Start Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996   Start Trial   Start Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Premature patent expiration for: CRIXIVAN

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
  Start Trial CRIXIVAN   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Baxter
McKesson
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.